01:07 , Jan 8, 2019 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Staphylococcus Cell culture and mouse studies suggest the MRGPRX2 activator mastoparan could help treat Staphylococcus aureus skin infection. In cell-based gene reporter assays, the wasp venom toxin mastoparan activated MRGPRX2-mediated phosphorylation of PLC1, which...
08:00 , Jan 29, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: MAS-related GPR member X2 (MRGPRX2)

Inflammation INDICATION: Allergy Mouse studies suggest inhibiting MRGPRX2 could help prevent drug-induced pseudo-allergic reactions, which do not involve IgE. In mast cells from MRGPRX2-knockout mice, pseudo-allergy-inducing drugs decreased calcium flux and histamine release compared with...
08:00 , Jan 22, 2015 |  BC Innovations  |  Targets & Mechanisms

Pseudo-allergy exposed

The perpetual worry for clinicians in administering injectable drugs is the chance they will induce allergic-type reactions either at the site of injection, or systemically if given during surgery. The problem turns out to be...
08:00 , Mar 5, 2007 |  BioCentury  |  Tools & Techniques

Predicting active peptides

Compugen Ltd. says it has developed an in silico discovery engine for peptides that bind GPCRs. So far, the engine has yielded eight peptides with dose-dependent activity, and CGEN plans to advance two into preclinical...